[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336389-105":59,"doc-detail-336389-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","validating-risk-prediction-models-for-multiple-primaries-and-competing-cancer-outcomes-in-families-with-li-fraumeni-syndrome-using-clinically-ascertained-data","Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data","","A clinical utility gap exists between developing and disseminating risk prediction models in real-world settings. This study validates established models for Li-Fraumeni syndrome using genetic counseling data with incomplete information collected during routine risk assessment at MD Anderson Cancer Center, contrasting performance against research cohorts built with meticulous protocols. Using LFSPRO software, discrimination and calibration were evaluated to quantify prediction accuracy for TP53 mutations and subsequent cancer onset.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/validating-risk-prediction-models-for-multiple-primaries-and-competing-cancer-outcomes-in-families-with-li-fraumeni-syndrome-using-clinically-ascertained-data/336389/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/validating-risk-prediction-models-for-multiple-primaries-and-competing-cancer-outcomes-in-families-with-li-fraumeni-syndrome-using-clinically-ascertained-data/336389.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"How did the models perform for predicting TP53 mutations and second cancers?","Question",{"text":112,"@type":113},"For deleterious TP53 mutations, the model achieved an AUC of 0.78 with an observed/expected ratio of 1.66. For second cancer onset, the LFSPRO.MPC model yielded an AUC of 0.70.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},336389,1790680096,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":19,"preview_urls":138},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","Original Reports | Cancer Prevention and Control  \nValidating Risk Prediction Models for Multiple Primaries  \nand Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data  \nNam H. Nguyen, MS1,2; Elissa B. Dodd-Eaton, MPH1; Jessica L. Corredor, MS, CGC3; Jacynda Woodman-Ross, MS, CGC3; Sierra Green, MPH3; Angelica M. Gutierrez, MS4 ; Banu K. Arun, MD3,4 ; and Wenyi Wang, PhD1   \nDOI [https://doi.org/10.1200/JCO.23.01926](https://doi.org/10.1200/JCO.23.01926)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | There exists a barrier between developing and disseminating risk prediction models in clinical settings. We hypothesize that this barrier may be lifted by demonstrating the utility of these models using incomplete data that are collected in real clinical sessions, as compared with the commonly used research cohorts that are meticulously collected. |\n| MATERIALS\u003Cbr>AND METHODS | Genetic counselors (GCs) collect family history when patients (ie, probands) come to MD Anderson Cancer Center for risk assessment of Li-Fraumeni syndrome, a genetic disorder characterized by deleterious germline mutations in the TP53 gene. Our clinical counseling-based (CCB) cohort consists of 3,297 individuals across 124 families (522 cases of single primary cancer and 125 cases of multiple primary cancers) . We applied our software suite LFSPRO to make risk predictions and assessed performance in discrimination using AUCand in calibration using observed/expected (O/E) ratio. |\n| RESULTS | For prediction of deleterious TP53 mutations, we achieved an AUC of 0.78 (95% CI, 0.71 to 0.85) and an O/E ratio of 1.66 (95% CI, 1.53 to 1.80) . Using the LFSPRO.MPC model to predict the onset of the second cancer, we obtained an AUC of 0.70 (95% CI, 0.58 to 0.82) . Using the LFSPRO.CS model to predict the onset of different cancer types as the ﬁrst primary, we achieved AUCs between 0.70 and 0 . 83 for sarcoma, breast cancer, or other cancers combined. |\n| CONCLUSION | We describe a study that ﬁlls in the critical gap in knowledge for the utility of risk prediction models. Using a CCB cohort, our previously validated models have demonstrated good performance and outperformed the standard clinical criteria. Our study suggests that better risk counseling may be achieved by GCs using these already-developed mathematical models. |\n\nACCOMPANYING CONTENT  \n Data Supplement  \nAccepted February 7, 2024 Published April 3, 2024  \nJ Clin Oncol 42:2186-2195 © 2024 by American Society of Clinical Oncology  \nView Online Article  \nLicensed under the Creative  \nCommons Attribution 4.0 License  \nINTRODUCTION  \nLi-Fraumeni syndrome (LFS) is a hereditary cancer syndrome identiﬁed by deleterious germline mutations in the TP53 tumor suppressor gene.1 Patients with LFS are at signiﬁcantly increased risks of many cancer types.1-3 The lifetime risks are 93% and 73% for women and men, respectively,4 with a 50% risk of second primary malignancy for cancer.5 Conversations with patients regarding genetic testing and cancer screening have been challenging, partly because genetic counselors (GCs) could only provide general, as compared with personalized, cancer risks associated with LFS.6 Risk prediction models have been developed for other hereditary cancer syndromes, such as the  \nhereditary breast and ovarian cancer syndrome and its associated genes BRCA1/2 . Among those, the TyrerCuzick,7 BRCAPRO,8 and CanRisk9 ,10 models are used in the current National Comprehensive Cancer Network (NCCN) guidelines (version 4.2024) to facilitate recommendation of at-risk individuals for testing of breast cancer susceptibility genes. LFS, however, remained an untouched area until recently. We developed two models for families with LFS: (1) a competing-risk model that predicts cancerspeciﬁc (CS) risks for the ﬁrst primary11 and (2) a recurrent event model that extends the prediction to multiple primary cancer (MPC) .12 These models were trained on an LFS cohort rich in ","cbCairieqkzdkztW","https://ap.wps.com/l/cbCairieqkzdkztW","pdf",689293,11,"English","# Abstract\n# Purpose\n# Materials and Methods\n# Results\n# Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"How did the models perform for predicting TP53 mutations and second cancers?\",\"answer\":\"For deleterious TP53 mutations, the model achieved an AUC of 0.78 with an observed/expected ratio of 1.66. For second cancer onset, the LFSPRO.MPC model yielded an AUC of 0.70.\"}]","Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data | PDF",1790014818,28,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb869d1e278041c83109866ef57f2c2c.webp",983,1315,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5a45a1813d1589b194d91532f70b6e4.webp",982,1314,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e5f965c0eac7f71d767faa31dfd7122.webp",981,1312,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67e733d1f59a430229256c9daf5f2182.webp",980,1311]